Synthesis and evaluation of Antibody conjugated to cyclical peptide toxin drug for the treatment of multi-drug resistant cancer cells

Antibody Drug Conjugates (ADC) are an emerging class of drugs that combine antibodies and a drug payload. The antibody cargoes the drug payload to specific targeted cells improving both safety and efficacy. To date that are 8 FDA approved ADC drugs all for oncology application using small molecule drugs. Although these ADCs with small molecules […]

Read More